drugset / Trial / NCT00784940

ATAC - Bone Density Sub-Protocol

NCT00784940

Phase 3 Completed 308 enrolled AstraZeneca
RandomizedParallel-groupDouble-blind

Summary

To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.

Timeline

Start
1998-06
Primary completion
2005-03
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastrozole Other / unclassified 1 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral

Indications